Stefan Johan Koppelman

Title: Stefan Johan Koppelman: Innovator in Peanut Allergy Treatment

Introduction

Stefan Johan Koppelman is a notable inventor based in De Bilt, Netherlands. He has made significant contributions to the field of immunotherapy, particularly in the treatment of peanut allergies. His innovative approach aims to improve the quality of life for individuals suffering from this common allergy.

Latest Patents

Koppelman holds a patent for "Pharmaceutical formulations and the use thereof for the treatment of peanut allergy." This invention relates to compositions that can be utilized in immunotherapy for mammals, including humans, who are affected by peanut allergies. The patent details the use of modified whole peanut extracts combined with pharmaceutically acceptable diluents and excipients. Specifically, it focuses on a reduced and subsequently alkylated whole peanut extract, which includes soluble peanut kernel proteins such as Ara h1, Ara h2, and Ara h6. This formulation is designed to desensitize the immune system of mammals suffering from allergies and to provide prophylactic treatment for those at high risk of developing such allergies.

Career Highlights

Koppelman is associated with Hal Allergy Holding B.V., a company dedicated to advancing allergy treatments. His work in this organization has been pivotal in developing innovative solutions for allergy sufferers.

Collaborations

One of his notable collaborators is Joanna Paulina Maria Van Der Kleij. Their partnership has contributed to the advancement of research and development in the field of allergy treatments.

Conclusion

Stefan Johan Koppelman is a key figure in the innovation of treatments for peanut allergies, with a focus on immunotherapy. His contributions through patents and collaborations continue to pave the way for advancements in allergy management.